Gerard J. Socie
Expertise in
28
conditions

Gerard J. Socie

Hematology Transplantation, St. Louis Hospital, 
Paris, FR 
Expertise in
28
conditions
Hematology Transplantation, St. Louis Hospital, 
Paris, FR 

Overview

Gerard Socie practices practicing medicine in Paris, France.

Mr. Socie is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Aplastic Anemia, Bone Marrow Transplant, and Bone Graft.

He is actively involved in clinical research, co-authoring 545 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Hematology Transplantation, St. Louis Hospital, Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy
Enrollment Status: Terminated
Publish Date: May 24, 2022
Intervention Type: Drug, Biological, Procedure
Study Drugs: ATIR101 Ex Vivo-Depleted T Lymphocyte-Enriched Leukocyte, Cyclophosphamide
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens
Enrollment Status: Completed
Publish Date: July 30, 2020
Intervention Type: Drug
Study Phase: Phase 3
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease
Enrollment Status: Terminated
Publish Date: January 30, 2020
Intervention Type: Biological
Study Phase: Phase 3
View 3 Less Clinical Trials

544 Total Publications

Endpoints for clinical allograft trials; GRFS should not be abandoned.
Endpoints for clinical allograft trials; GRFS should not be abandoned.
Journal: Blood advances
Published: June 15, 2026

Frequently Asked Questions about Gerard J. Socie

Is Gerard J. Socie a top-rated expert for Chronic Graft Versus Host Disease (cGvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Gerard J. Socie is classified as an Elite expert for Chronic Graft Versus Host Disease (cGvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Gerard J. Socie participate in research or clinical trials?

Yes. Gerard J. Socie has published 544 articles and abstracts on conditions like Chronic Graft Versus Host Disease (cGvHD). You can view a list of Gerard J. Socie's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Socie's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 18 Advanced Conditions
View All 41 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile